This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • PROSEEK: A Phase 2 Study In Early Parkinson's Dise...
Clinical trial

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Read time: 2 mins
Last updated:18th Feb 2019
Identifier: NCT03655236

The study is conducted to evaluate the efficacy, safety and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy.

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 504 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease
Actual Study Start Date: February 18, 2019
Estimated Primary Completion Date: February 2021
Estimated Study Completion Date: February 2021

- Experimental:
K0706, low dose
- Experimental: K0706, high dose
- Placebo Comparator: Placebo, placebo capsules

Category Value
Date last updated at source 2019-09-30
Study type(s) Interventional
Expected enrolment 504
Study start date 2019-02-18
Estimated primary completion date 2021-02-01

View full details